Iron deficiency anaemia in patients with inflammatory bowel disease MedDRA version: 9.1 Level: LLT Classification code 10055736 Term: Iron deficiency anaemia secondary to blood loss (chronic)
Conditions
Sponsors
Vifor (International) Inc.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients will be entered into this study only if they meet all of the following criteria: •Signed informed consent. •Non-anaemic patients treated in the FERGI CORRECTION study (Hb =12 g/dL female, =13 g/dL male), independent of ferritin value. • If VitB12/folate levels are below normal range, an appropriate supplementation should be started. •Females of child-bearing potential must have a negative urine pregnancy test at screening and be practising an acceptable method of birth control during the study and for up to 1 month after the last dose of study medication. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Patients will not be entered into this study if they meet any of the following criteria: •Chronic alcohol abuse (alcohol consumption >20 g/day). •Presence of portal hypertension with oesophageal varices. •History of erythropoietin, intravenous or oral iron therapy, or blood transfusion in 12 weeks prior to screening. •Known hypersensitivity to FERINJECT®. •History of acquired iron overload. •Myelodysplastic syndrome. •Pregnancy or lactation. •Known active infection, clinically significant overt bleeding, active malignancy. •Known chronic renal failure. •Surgery with relevant blood loss (defined as Hb drop 3 times the upper limit of normal range. •Known human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS), hepatitis B virus (HBV) or hepatitis C virus (HCV) infection. •Inability to fully comprehend and/or perform study procedures in the investigator’s opinion. •Participation in any other interventional study (except correction study) within 1 month prior to screening. •Body weight <35 kg. •Significant cardiovascular disease, including myocardial infarction within 12 months prior to study inclusion, congestive heart failure NYHA (New York Heart Association) grade III or IV, or poorly controlled hypertension according to the judgment of the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To evaluate the efficacy and safety of a standardised maintenance dosage regimen of FERINJECT® versus placebo in the correction of iron deficiency and prevention of anaemia in treatment over 8 months.;Secondary Objective: •To evaluate the efficacy of treatment with FERINJECT® in respect to health related Quality of Life (QoL) over 8 months. •To evaluate the safety and tolerability of a standardised maintenance dosage regimen of FERINJECT®. •To evaluate the effect of treatment with FERINJECT® over 8 months on the developing of underlying disease. ;Primary end point(s): Time to development of anaemia (Hb <12 g/dL [female], <13 g/dL [male]) in 8 months after randomisation – difference between the treatment groups. | — |
Countries
Austria, Denmark, Estonia, Germany, Lithuania, Spain, Sweden, United Kingdom
Outcome results
None listed